• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

Interview With Charles Gore, Medicines Patent Pool Executive Director

22/03/2019 by Intellectual Property Watch 1 Comment

Charles Gore took over the role of Executive Director at the Medicines Patent Pool in July 2018, just after its board decided to greatly expand its mandate into essential medicines. Nine months into his term, IP-Watch’s William New talked with him about his role and how the expansion is going.

Filed Under: Features, Inside Views, IP Policies, Language, Themes, Venues, English, Health & IP, Other International Orgs, Patents/Designs/Trade Secrets, WHO

Will US Drug Pricing Politics Change Intimidation Practices Globally?

05/03/2019 by Intellectual Property Watch 2 Comments

Fifa Rahman

Fifa Rahman writes: The global health world, particularly as concerns skyrocketing drug prices and patent abuse, is in a unique space in time. Recently, the Office of the United States Trade Representative (USTR) has been carrying on as per usual. It has threatened the Malaysian and Colombian governments at numerous junctures to prevent them from issuing compulsory licences – a completely legal mechanism which the US uses regularly – to access generic hepatitis C drugs. The Trump Administration has sent delegations to global health agencies in Geneva to intimidate them into reducing, or hiding, work on TRIPS flexibilities and fairer drug pricing.

Filed Under: Features, Inside Views, IP Policies, Language, Themes, Venues, Asia/Pacific, Bilateral/Regional Negotiations, English, Health & IP, Human Rights, North America, Patents/Designs/Trade Secrets, Regional Policy, WTO/TRIPS

European Patent Office Report Compares Compulsory Licensing Practices By Country

01/03/2019 by Intellectual Property Watch Leave a Comment

The European Patent Office has published a report detailing differences in the laws and procedures of European countries for the granting of compulsory licences.

Filed Under: IP-Watch Briefs, IP Policies, Language, Themes, Venues, English, Europe, Health & IP, Patents/Designs/Trade Secrets, Regional Policy

Patents Under Debate As Pharma Executives Face US Senate Committee

27/02/2019 by William New, Intellectual Property Watch Leave a Comment

Executives of seven large pharmaceutical companies faced questioning yesterday from the United States Senate Finance Committee over high drug prices in the US, especially compared with other developed countries. One issue that came under the microscope was patents.

Filed Under: IP Policies, Language, Subscribers, Themes, Venues, English, Health & IP, Innovation/ R&D, Lobbying, North America, Patents/Designs/Trade Secrets, Regional Policy

New Research Study Describes DNDi As A “Commons” For Public Health

25/02/2019 by David Branigan, Intellectual Property Watch Leave a Comment

Since 2003, Drugs for Neglected Diseases Initiative (DNDi) has worked to meet the public health needs of neglected populations by filling gaps in drug development left by the for-profit pharmaceutical industry. A new research study by the French Development Agency analysed DNDi’s unique product development partnership (PDP) model, and found that it “illustrate[s] what can be presented as a ‘commons’ within the area of public health.”

Filed Under: IP Policies, Language, Themes, Venues, English, Europe, Health & IP, Innovation/ R&D, Patents/Designs/Trade Secrets, Regional Policy

In Memoriam: Dilip Shah (1941-2019)

25/02/2019 by Intellectual Property Watch, Intellectual Property Watch Leave a Comment

Dilip Shah was passionately committed to the twin causes of promoting fair access to medicines around the world, and to the success of the local Indian pharmaceutical industry. A bright light is out, writes Prof. Frederick Abbott.

Filed Under: IP Policies, Language, Themes, Venues, Asia/Pacific, English, Health & IP, Patents/Designs/Trade Secrets, Regional Policy

D G Shah, Founder Of Indian Pharmaceutical Alliance, Dies At Age 77: Economic Times

22/02/2019 by William New, Intellectual Property Watch 1 Comment

Dilip Shah, founder of the Indian Pharmaceutical Alliance (IPA) the organisation that represented the interests of Indian drug makers passed away in Mumbai on Friday. He was 77. Known in the industry as “DG”, Mr Shah started the IPA when the Indian pharma companies were trying to find their feet in the global pharma landscape that was dominated by the multinational pharma companies predominantly based out of Europe and USA. Shah who himself spent most of his career with the MNC drug companies …

Filed Under: IP Policies, Language, Themes, Venues, Asia/Pacific, Development, English, Health & IP, Innovation/ R&D, Lobbying, Patents/Designs/Trade Secrets, Regional Policy

Faced With Unreasonable Medicines Prices, The Netherlands Introduces Pharmacy Exemption In Patent Law

22/02/2019 by Intellectual Property Watch Leave a Comment

Ellen ‘t Hoen writes: On 1 February 2019, article 53(3), second sentence of the Dutch Patent Act 1995 came into force introducing a patent exemption for the preparation of medicines in a pharmacy.

Filed Under: Features, Inside Views, IP Policies, Language, Themes, Venues, English, Europe, Health & IP, Innovation/ R&D, Patents/Designs/Trade Secrets, Regional Policy

WTO IP Council: Praise For Public-Private Partnerships, Use Of Competition Law To Fight High Drug Prices

18/02/2019 by Catherine Saez, Intellectual Property Watch Leave a Comment

At the World Trade Organization Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS) – which met on 13 February and finished in one day – discussions on IP and innovation, and IP and the public interest delineated points of views but also provided concrete examples of successful use of public-private partnerships, and use of competition law to prevent excessive pricing.

Filed Under: IP Policies, Language, Subscribers, Themes, Venues, Development, English, Health & IP, Patents/Designs/Trade Secrets, Technical Cooperation/ Technology Transfer, WTO/TRIPS

Agreement On SPC Manufacturing Waiver Reached, Benefitting EU Generic, Biosimilar Industry

14/02/2019 by David Branigan, Intellectual Property Watch 2 Comments

The European Council reached a political agreement today on the SPC Manufacturing Waiver, which will allow the manufacture of generic and biosimilar medicines in the European Union for export and stockpiling during the period of extended patent protection provided for by the EU. This waiver will enable EU generic and biosimilar industries to benefit from sales outside the EU where patents have already expired, and to prepare to provide the EU market as soon as the extended period of patent protection ends.

Filed Under: IP Policies, Language, Subscribers, Themes, Venues, English, Europe, Health & IP, Patents/Designs/Trade Secrets, Regional Policy

  • 1
  • 2
  • 3
  • …
  • 199
  • Next Page »
  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2022 · Global Policy Reporting